Cargando…
Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models
Metronomic chemotherapy refers to the minimum biologically effective doses of a chemotherapy agent given as a continuous regimen without extended rest periods. Drug repurposing is defined as the use of an already known drug for a new medical indication, different from the original one. In oncology t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429183/ https://www.ncbi.nlm.nih.gov/pubmed/32850009 http://dx.doi.org/10.18632/oncotarget.27694 |
_version_ | 1783571236337483776 |
---|---|
author | Mainetti, Leandro E. Rico, María José Kaufman, Cintia Daniela Grillo, Monica Carolina Guercetti, Julian Baglioni, María Virginia Del Giúdice, Antonela Capitani, Maria Celeste Fusini, Matias Rozados, Viviana Rosa Scharovsky, O. Graciela |
author_facet | Mainetti, Leandro E. Rico, María José Kaufman, Cintia Daniela Grillo, Monica Carolina Guercetti, Julian Baglioni, María Virginia Del Giúdice, Antonela Capitani, Maria Celeste Fusini, Matias Rozados, Viviana Rosa Scharovsky, O. Graciela |
author_sort | Mainetti, Leandro E. |
collection | PubMed |
description | Metronomic chemotherapy refers to the minimum biologically effective doses of a chemotherapy agent given as a continuous regimen without extended rest periods. Drug repurposing is defined as the use of an already known drug for a new medical indication, different from the original one. In oncology the combination of these two therapeutic approaches is called “Metronomics”. The aim of this work is to evaluate the therapeutic effect of cyclophosphamide in a metronomic schedule in combination with the repurposed drug losartan in two genetically different mice models of triple negative breast cancer. Our findings showed that adding losartan to metronomic cyclophosphamide significantly improved the therapeutic outcome. In both models the combined treatment increased the mice’s survival without sings of toxicity. Moreover, we elucidated some of the mechanisms of action involved, which include a decrease of intratumor hypoxia, stimulation of the immune response and remodeling of the tumor microenvironment. The remarkable therapeutic effect, the lack of toxicity, the low cost of the drugs and its oral administration, strongly suggest its translation to the clinical setting in the near future. |
format | Online Article Text |
id | pubmed-7429183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-74291832020-08-25 Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models Mainetti, Leandro E. Rico, María José Kaufman, Cintia Daniela Grillo, Monica Carolina Guercetti, Julian Baglioni, María Virginia Del Giúdice, Antonela Capitani, Maria Celeste Fusini, Matias Rozados, Viviana Rosa Scharovsky, O. Graciela Oncotarget Research Paper Metronomic chemotherapy refers to the minimum biologically effective doses of a chemotherapy agent given as a continuous regimen without extended rest periods. Drug repurposing is defined as the use of an already known drug for a new medical indication, different from the original one. In oncology the combination of these two therapeutic approaches is called “Metronomics”. The aim of this work is to evaluate the therapeutic effect of cyclophosphamide in a metronomic schedule in combination with the repurposed drug losartan in two genetically different mice models of triple negative breast cancer. Our findings showed that adding losartan to metronomic cyclophosphamide significantly improved the therapeutic outcome. In both models the combined treatment increased the mice’s survival without sings of toxicity. Moreover, we elucidated some of the mechanisms of action involved, which include a decrease of intratumor hypoxia, stimulation of the immune response and remodeling of the tumor microenvironment. The remarkable therapeutic effect, the lack of toxicity, the low cost of the drugs and its oral administration, strongly suggest its translation to the clinical setting in the near future. Impact Journals LLC 2020-08-11 /pmc/articles/PMC7429183/ /pubmed/32850009 http://dx.doi.org/10.18632/oncotarget.27694 Text en http://creativecommons.org/licenses/by/3.0/ Copyright: Mainetti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Mainetti, Leandro E. Rico, María José Kaufman, Cintia Daniela Grillo, Monica Carolina Guercetti, Julian Baglioni, María Virginia Del Giúdice, Antonela Capitani, Maria Celeste Fusini, Matias Rozados, Viviana Rosa Scharovsky, O. Graciela Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models |
title | Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models |
title_full | Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models |
title_fullStr | Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models |
title_full_unstemmed | Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models |
title_short | Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models |
title_sort | losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429183/ https://www.ncbi.nlm.nih.gov/pubmed/32850009 http://dx.doi.org/10.18632/oncotarget.27694 |
work_keys_str_mv | AT mainettileandroe losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT ricomariajose losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT kaufmancintiadaniela losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT grillomonicacarolina losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT guercettijulian losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT baglionimariavirginia losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT delgiudiceantonela losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT capitanimariaceleste losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT fusinimatias losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT rozadosvivianarosa losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels AT scharovskyograciela losartanimprovesthetherapeuticeffectofmetronomiccyclophosphamideintriplenegativemammarycancermodels |